Sildenafil (Viagra®): A Pharmacokinetic (PK) Review

Tirtha Nandi *

Department of Pharmaceutical Sciences, Temple University School of Pharmacy, United States of America.

Kushal Biswas

Department of Biomedical and Nutritional Sciences, Zuckerberg College of Health Sciences, University of Massachusetts Lowell, United States of America.

Sifat Sharmin

Cereal and Food Science Technology Department, North Dakota State University, United States of America.

*Author to whom correspondence should be addressed.


Abstract

Introduction: Erectile Dysfunction (ED) is the inability to achieve or/and maintain a sufficient penile erection for successful, satisfactory, and pleasant vaginal intercourse. National Institute of Health's division of NIDDK (National Institute of Diabetes and Digestive and Kidney Diseases) defines erectile dysfunction as a condition in which one person cannot get or keep an erection firm enough for satisfactory sexual intercourse. The usual symptoms include problems achieving a solid erection, difficulties maintaining the erected condition of the penis, and decreased sexual desire. Several factors can contribute to these penile disorders. These include neurogenic injury, endocrinological disorders, drug-affected pathology, cardiovascular disease, etc. The aim of this review was to discuss the mechanism, structure activity relation (SAR), and pharmacokinetic properties of sildenafil.

Methods: A careful literature search was conducted to compile all the recent information available for sildenafil PK. Primary literature searches included PubMed, Google Scholar, Wiley online resources, etc.

Results: After the completion of the lengthy process of drug discovery, sildenafil citrate was approved by the FDA to be used for erectile dysfunction in March 1998. It was the very first oral treatment for erectile dysfunction.

Conclusion: Although several selective PDE 5 inhibitors are available now, sildenafil citrate is still one of the most prescribed drugs for treating penile erectile disorders.

Keywords: Erectile dysfunction, sex, Viagra®, intercourse, PDE5i


How to Cite

Nandi, T., Biswas, K., & Sharmin, S. (2022). Sildenafil (Viagra®): A Pharmacokinetic (PK) Review. Journal of Advances in Medicine and Medical Research, 34(22), 300–315. https://doi.org/10.9734/jammr/2022/v34i224817

Downloads

Download data is not yet available.

References

Lue TF. Erectile dysfunction. New England Journal of Medicine. 2000;342(24):1802-1813.

Prins J, et al. Prevalence of erectile dysfunction: A systematic review of population-based studies. International Journal of Impotence Research. 2002;14(6):422-432.

Shamloul R, Ghanem H. Erectile dysfunction. The Lancet. 2013;381(9861): 153-165.

Hanson-Divers C, et al. Health outcomes variables important to patients in the treatment of erectile dysfunction. The Journal of Urology. 1998;159(5):1541-1547.

Mihmanli I, Kantarci F. Erectile dysfunction. Elsevier.

Pizzol D, et al. Prevalence of erectile dysfunction in patients with chronic kidney disease: A systematic review and meta-analysis. International Journal of Impotence Research. 2021;33(5):508-515.

Rinkūnienė E, et al. The prevalence of erectile dysfunction and its association with cardiovascular risk factors in patients after myocardial infarction. Medicina. 2021;57(10):1103.

Selvin E, Burnett AL, Platz EA. Prevalence and risk factors for erectile dysfunction in the US. The American Journal of Medicine. 2007;120(2):151-157.

Arora S, et al. Sildenafil in ophthalmology: An update. Survey of Ophthalmology; 2021.

Ouranidis A, et al. Sildenafil 4.0-Integrated synthetic chemistry, formulation and analytical strategies effecting immense therapeutic and societal impact in the fourth industrial era. Pharmaceuticals. 2021;14(4):365.

Andersson KE. PDE5 inhibitors–pharmacology and clinical applications 20 years after sildenafil discovery. British Journal of Pharmacology. 2018;175(13):2554-2565.

Tripathi AS, Mazumder PM, Chandewar AV. Sildenafil, a phosphodiesterase type 5 inhibitor, attenuates diabetic nephropathy in STZ-induced diabetic rats. Journal of Basic and Clinical Physiology and Pharmacology. 2016;27(1):57-62.

Van Driel MF. Physiology of penile erection-a brief history of the scientific understanding up till the eighties of the 20th century. Sexual Medicine. 2015;3(4):349-357.

Leung AC, Christ GJ, Melman A. Physiology of penile erection and pathophysiology of erectile dysfunction. Atlas of Male Sexual Dysfunction. 2004;1-25.

McKenna KE. Central control of penile erection. International Journal of Impotence Research. 1998;10:S25-34.

McKenna KE. Central nervous system pathways involved in the control of penile erection. Annual Review of Sex Research. 1999;10(1):157-183.

McKenna KE. Some proposals regarding the organization of the central nervous system control of penile erection. Neuroscience & Biobehavioral Reviews. 2000;24(5):535-540.

Mitidieri E, et al. Pharmacology and perspectives in erectile dysfunction in man. Pharmacology & Therapeutics. 2020;208:107493.

Sangiorgi G, et al. Anatomy, pathophysiology, molecular mechanisms, and clinical management of erectile dysfunction in patients affected by coronary artery disease: A review. Biomedicines. 2021;9(4):432.

McVary KT, et al. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: A randomized, double-blind trial. The Journal of Urology. 2007;177(3):1071-1077.

Ponholzer A, Rauchenwald M, Madersbacher S. Re: Sildenafil Citrate Improves Erectile Function and Urinary Symptoms in Men With Erectile Dysfunction and Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: A Randomized, Double-Blind Trial: McVary KT, Monnig W, Camps JL Jr, Young JM, Tseng LJ, van den Ende J Urol G. 2007;177:1071-1077. The Journal of Urology. 2007;178(3):1121-1123.

Mulhall JP, et al. Assessment of the impact of sildenafil citrate on lower urinary tract symptoms in men with erectile dysfunction. The Journal of Sexual Medicine. 2006;3(4):662-667.

Gresser U, Gleiter CH. Erectile dysfunction: Comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil-review of the literature. European Journal of Medical Research. 2002;7(10):435-446.

Abrams D, Schulze-Neick I, Magee AG. Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension. Heart. 2000;84(2):e4-e4.

Tzoumas N, et al. Established and emerging therapeutic uses of PDE type 5 inhibitors in cardiovascular disease. British Journal of Pharmacology. 2020;177(24):5467-5488.

Rademacher JG, et al. Combination therapy with bosentan and sildenafil for refractory digital ulcers and Raynaud’s phenomenon in a 30-year-old woman with systemic sclerosis: Case report and literature review. Journal of Scleroderma and Related Disorders. 2020;5(2):159-164.

Haider M, et al. The potential role of sildenafil in cancer management through EPR augmentation. Journal of Personalized Medicine. 2021;11(6):585.

Iratni R, Ayoub MA. Sildenafil in combination therapy against cancer: A literature review. Current Medicinal Chemistry. 2021;28(11):2248-2259.

Muniyan S, et al. Sildenafil potentiates the therapeutic efficacy of docetaxel in advanced prostate cancer by stimulating NO-cGMP signaling. Clinical Cancer Research. 2020;26(21):5720-5734.

Cruz-Burgos M, et al. New approaches in oncology for repositioning drugs: the case of PDE5 inhibitor sildenafil. Frontiers in Oncology. 2021;11:627229.

Eltony SA, Abdelhameed SY. Effect of chronic administration of sildenafil citrate (Viagra) on the histology of the retina and optic nerve of adult male rat. Tissue and Cell. 2017;49(2):323-335.

Ibrahim MA, et al. Sildenafil ameliorates Alzheimer disease via the modulation of vascular endothelial growth factor and vascular cell adhesion molecule-1 in rats. Human & Experimental Toxicology. 2021;40(4):596-607.

Sanders O. Sildenafil for the treatment of Alzheimer’s disease: A systematic review. Journal of Alzheimer's Disease Reports. 2020;4(1):91-106.

Ghofrani HA, Osterloh IH, Grimminger F. Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nature reviews Drug Discovery. 2006;5(8):689-702.

Osterloh IH. The discovery and development of Viagra®(sildenafil citrate), in Sildenafil. Springer. 2004;1-13.

Campbell SF. Science, art and drug discovery: A personal perspective. Clinical Science. 2000;99(4):255-260.

Terrett NK, et al. Sildenafil (VIAGRATM), a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction. Bioorganic & Medicinal Chemistry Letters. 1996;6(15):1819-1824.

Walker DK. Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. Xenobiotica. 1999;29(3):297-310.

Abbott D, et al. Preclinical safety profile of sildenafil. International Journal of Impotence Research. 2004;16(6): 498-504.

Choi S, et al. Efficacy of vardenafil and sildenafil in facilitating penile erection in an animal model. Journal of Andrology. 2002;23(3):332-337.

Gupta M, Kovar A, Meibohm B. The clinical pharmacokinetics of phosphodiesterase‐5 inhibitors for erectile dysfunction. The Journal of Clinical Pharmacology. 2005;45(9):987-1003.

Mehrotra N, et al. The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy. International Journal of Impotence Research. 2007;19(3):253-264.

Wu CY, Benet LZ. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharmaceutical Research. 2005;22(1):11-23.

Research GV. Erectile dysfunction drugs market size, share & trends analysis report by product (Viagra, Cialis, Zydena, Levitra, Stendra), by region (North America, Europe, APAC, Latin America, MEA), and segment forecasts. 2022 - 2030.

[cited 2022 09.22.2022]

Available:https://www.grandviewresearch.com/industry-analysis/erectile-dysfunction-drugs-market/methodology